Literature DB >> 16032697

Prevalence of 9p21 deletions in UK melanoma families.

Sushila H Mistry1, Claire Taylor, Juliette A Randerson-Moor, Mark Harland, Faye Turner, Jennifer H Barrett, Linda Whitaker, Robert B Jenkins, Margaret A Knowles, Julia A Newton Bishop, D Timothy Bishop.   

Abstract

Although the CDKN2A gene has been shown to be the major genetic determinant governing high-penetrance susceptibility to melanoma, there remains a significant proportion of melanoma pedigrees in which germline mutations of CDKN2A have not been identified. We have therefore studied the prevalence of germline 9p deletions encompassing the CDKN2 locus in melanoma pedigrees, using multiplex ligation-dependent probe amplification. Germline deletions were found in 3 of 93 UK pedigrees, with no previously identified CDKN2A mutations. A hemizygous deletion of CDKN2A exon 1beta previously reported by this group was confirmed in one family and identified in a second. Microsatellite analysis determined that these two families were ancestrally related. In the third family, a novel p16 hemizygous deletion involving CDKN2A exons 1alpha, 2, and 3 was detected. An additional 9p21 deletion reported previously in a USA melanoma-neural system tumor family was shown to involve CDKN2A exon 1beta, and not p16. The CDKN2A exon 1beta deletions provide further evidence that this tumor suppressor gene is important in melanoma-neural system tumor susceptibility, but do not exclude the possibility of a novel gene or regulatory element also being deleted in this region. Deletions at 9p21 are rare and explain only a small proportion of melanoma susceptibility. This study is the first to comprehensively exclude deletions in melanoma-prone families with no previously identified CDKN2A mutations. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16032697     DOI: 10.1002/gcc.20238

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

Review 1.  An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies.

Authors:  Maria J Baker; Alisa M Goldstein; Patricia L Gordon; Kimberly S Harbaugh; Heath B Mackley; Michael J Glantz; Joseph J Drabick
Journal:  J Med Genet       Date:  2016-01-21       Impact factor: 6.318

2.  Frequent p16-independent inactivation of p14ARF in human melanoma.

Authors:  Daniel E Freedberg; Sushila H Rigas; Julie Russak; Weiming Gai; Margarita Kaplow; Iman Osman; Faye Turner; Juliette A Randerson-Moor; Alan Houghton; Klaus Busam; D Timothy Bishop; Boris C Bastian; Julia A Newton-Bishop; David Polsky
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

3.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

Review 4.  Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.

Authors:  Zizhen Ming; Su Yin Lim; Helen Rizos
Journal:  Biomolecules       Date:  2020-10-15

5.  Somatic mutations in exocrine pancreatic tumors: association with patient survival.

Authors:  P Sivaramakrishna Rachakonda; Andrea S Bauer; Huaping Xie; Daniele Campa; Cosmeri Rizzato; Federico Canzian; Stefania Beghelli; William Greenhalf; Eithne Costello; Michaela Schanne; Anette Heller; Aldo Scarpa; John P Neoptolemos; Jens Werner; Markus Büchler; Jörg D Hoheisel; Kari Hemminki; Nathalia Giese; Rajiv Kumar
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

6.  The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Authors:  F Lesueur; M de Lichy; M Barrois; G Durand; J Bombled; M-F Avril; A Chompret; F Boitier; G M Lenoir; B Bressac-de Paillerets; Monique Baccard; Bertrand Bachollet; Pascaline Berthet; Valérie Bonadona; Jean-Marie Bonnetblanc; Olivier Caron; Jacqueline Chevrant-Breton; Jean-François Cuny; Stéphane Dalle; Michèle Delaunay; Liliane Demange; Julie De Quatrebarbes; Jean-François Doré; Marc Frénay; Jean-Pierre Fricker; Marion Gauthier-Villars; Paul Gesta; Sophie Giraud; Philippe Gorry; Florent Grange; Andrew Green; Laetitia Huiart; Nicolas Janin; Pascal Joly; Delphine Kérob; Christine Lasset; Dominique Leroux; Jean-Marc Limacher; Michel Longy; Sandrine Mansard; Karine Marrou; Tanguy Martin-Denavit; Christine Mateus; Eve Maubec; Laurence Olivier-Faivre; Vincent Orlandini; Pascal Pujol; Bruno Sassolas; Dominique Stoppa-Lyonnet; Luc Thomas; Pierre Vabres; Laurence Venat; Ewa Wierzbicka; Hélène Zattara
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

7.  Management of melanoma families.

Authors:  Wilma Bergman; Nelleke A Gruis
Journal:  Cancers (Basel)       Date:  2010-04-16       Impact factor: 6.639

8.  A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma.

Authors:  Simona Frigerio; Vittoria Disciglio; Siranoush Manoukian; Bernard Peissel; Gabriella Della Torre; Andrea Maurichi; Paola Collini; Barbara Pasini; Giacomo Gotti; Andrea Ferrari; Licia Rivoltini; Maura Massimino; Monica Rodolfo
Journal:  BMC Med Genet       Date:  2014-05-17       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.